CTRI/2017/03/008202RecruitingPhase 4
A 6 week prospective open label comparative study of efficacy and safety of vilazodone and fluoxetine in major depressive disorder
Mysore medical college and research institute0 sites72 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 4
- Status
- Recruiting
- Sponsor
- Enrollment
- 72
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •subjects diagnosed with major depressive disorder, first episode (according to DSM -V criteria) or recurrent episodes.
- •Age: 18-65 years.
- •Both sexes.
- •Subjects who give informed consent.
Exclusion Criteria
- •Severe depressive episode with suicidal/poor insight subject who is unable to give informed consent.
- •Subjects with any serious concurrent medical and psychiatric illness.
- •Presence of organic brain syndromes including delirium and dementia.
Investigators
Similar Trials
Not yet recruiting
Not Applicable
Comparison of Moxifloxacin plus Dexamethasone eye drops treatment for 6-weeks vs 2-weeks in patients with eye operation.CTRI/2019/02/017692Santhiram Medical College and General Hospital
Active, not recruiting
Not Applicable
A 6-week open label cross-over study with 2 different daily doses of Minirin® oral lyophilisate (120 µg and 240 µg) and 2 different daily doses of Minirin® tablet (0.2 mg and 2 x 0.2 mg) in children and adolescents with primary nocturnal enuresis (PNE) - PALATPrimary Nocturnal EnuresisMedDRA version: 6.1Level: LLTClassification code 10029453EUCTR2004-000593-32-SEFerring Pharmaceuticals A/S200
Active, not recruiting
Phase 1
A 6-week open label cross-over study with 2 different daily doses of Minirin® oral lyophilisate (120 µg and 240 µg) and 2 different daily doses of Minirin® tablet (0.2 mg and 2 x 0.2 mg) in children and adolescents with primary nocturnal enuresis (PNE)Primary Nocturnal EnuresisMedDRA version: 6.1 Level: low Classification code 10029453EUCTR2004-000593-32-GBFerring Pharmaceuticals A/S200
Active, not recruiting
Not Applicable
A 6-week open label cross-over study with 2 different daily doses of Minirin oral lyophilisate (120 µg and 240 µg) and 2 different daily doses of Minirin tablet (0.2 mg and 2 x 0.2 mg) in children and adolescents with primary nocturnal enuresis (PNE)Primary Nocturnal EnuresisMedDRA version: 6.1Level: lowClassification code 10029453EUCTR2004-000593-32-DEFerring Arzneimittel GmbH200
Active, not recruiting
Not Applicable
A 6-week open label cross-over study with 2 different daily doses of Minirin® oral lyophilisate (120 µg and 240 µg) and 2 different daily doses of Minirin® tablet (0.2 mg and 2 x 0.2 mg) in children and adolescents with primary nocturnal enuresis (PNE) - PALATPrimary Nocturnal EnuresisMedDRA version: 6.1Level: LLTClassification code 10029453EUCTR2004-000593-32-FIFerring Pharmaceuticals A/S200